Company Monitoring Page for Acceleron

latest headlines for company on cafepharma

Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH study
Fierce Pharma
Mon, 11/25/24 - 09:52 am
Tags:
Merck, Acceleron, Winrevair, sotatercept, PAH, clinical trials
Merck scores key FDA approval for pulmonary arterial hypertension drug Winrevair
Fierce Pharma
Wed, 03/27/24 - 11:22 am
Tags:
Merck, FDA, PAH, Winrevair, sotatercept, Acceleron
Sotatercept- the breakthrough PAH has been waiting for?
Clinical Trials Arena
Thu, 11/10/22 - 10:31 am
Tags:
Merck, sotatercept, Acceleron, PAH
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Fierce Biotech
Mon, 10/10/22 - 11:06 am
Tags:
Merck, Acceleron, clinical trials, sotatercept, PAH, pulmonary arterial hypertension
Merck cuts 170 jobs at Acceleron right on heels of $11.5B buyout
Fierce Pharma
Wed, 03/30/22 - 11:05 am
Tags:
Merck, Acceleron, M&A, layoffs, Cambridge
The top 10 biopharma M&A deals in 2021
Fierce Pharma
Tue, 01/18/22 - 10:53 am
Tags:
M&A, CSL, Vifor, Jazz Pharmaeuticals, GW Pharma, Novo Nordisk, Dicerna, Horizon Therapeutics, Viela Bio, Perrigo, HRA Pharma, Sanofi, Kadmon, Merck, Acceleron, Pfizer, Arena Pharmaceuticals, Translate Bio, Trillium Therapeutics, Amgen, Five Prime Therapeutics
Is Merck's Planned Acquisition of Acceleron in Trouble?
Motley Fool
Sat, 11/13/21 - 09:55 pm
Tags:
Merck, Acceleron, M&A
Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout
Fierce Pharma
Sun, 10/24/21 - 10:40 pm
Tags:
Bristol Myers Squibb, Acceleron, M&A, Aurinia Pharmaceuticals
Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report
Endpoints
Thu, 10/21/21 - 09:31 am
Tags:
Merck, Acceleron, M&A, Bristol Myers Squibb
Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention
BioSpace
Thu, 10/14/21 - 11:12 pm
Tags:
Merck, Acceleron, M&A, Bristol Myers Squibb
Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180
Fierce Pharma
Tue, 10/12/21 - 11:35 pm
Tags:
Merck, Pharma CEOs, Robert Davis, M&A, Acceleron
Is an Acquisition of Acceleron a Smart Move for Merck?
Motley Fool
Fri, 10/8/21 - 10:35 am
Tags:
Merck, M&A, Acceleron, PAH, Keytruda
Biopharma needs a biggie to avoid a down deal year
EP Vantage
Thu, 10/7/21 - 11:07 am
Tags:
M&A, Merck, Acceleron, Sanofi, Translate Bio, Amgen, Teneobio, Pfizer, Trillium, Perrigo, HRA Pharma
Trouble builds for Merck's $11.5B Acceleron buy as activist investor behind Gilead's Immunomedics deal says too early, too cheap
Fierce Pharma
Fri, 10/1/21 - 10:55 am
Tags:
Merck, Acceleron, M&A, investors, Avoro Capital
Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug
BioSpace
Thu, 09/30/21 - 12:01 am
Tags:
Merck, Acceleron, M&A, PAH
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
Endpoints
Tue, 09/28/21 - 12:15 am
Tags:
Merck, Acceleron, M&A, PAH, sotatercept
Rumor mill says Acceleron is speeding towards $11bn sale
Pharmaforum
Sun, 09/26/21 - 11:28 pm
Tags:
Acceleron, M&A
Acceleron, under threat of fines, reports out a negative study
RAPS.org
Wed, 05/26/21 - 12:00 am
Tags:
Acceleron, clinical trials, regulatory
Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Endpoints
Wed, 05/19/21 - 10:42 am
Tags:
Acceleron, sotatercept, PAH
The "Rare Disease Company Coalition" Launches to Share the Unique Challenges and Promise of Rare Disease Therapy Development to Support Continued Progress and Patient Access
Yahoo/Businesswire
Thu, 05/13/21 - 12:04 pm
Tags:
Rare Diseases, Rare Disease Company Coalition, drug development, drug discovery, Acceleron, Aeglea BioTherapeutics, Agios Pharmaceuticals, Alnylam, Harmony Biosciences, Orchard Therapeutics, Orphazyme, Sarepta Therapeutics, Taysha Gene Therapies, Ultragenyx

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.